Compare Crispr Therapeutics AG (CRSP) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Infosys Limited — how do they compare? Crispr Therapeutics AG trades at $50.5 (market cap $4.97B), while Infosys Limited trades at $11.16 (market cap $46.90B). The key difference: Infosys Limited is far larger — about 9.4× Crispr Therapeutics AG's market cap, and Infosys Limited pays a 4.74% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | INFY | |
|---|---|---|
Market Cap | $4.97B | $46.90B |
Sector | Health | Technology |
52-Week High | $76.78 | $20.22 |
52-Week Low | $44.34 | $10.49 |
Enterprise Value | $3.32B | $44.12B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
INFY trades at $11.50, up 5.12% today, with a bullish technical signal and strong profitability metrics including a 16.44% net income margin and 31.57% ROE. Recent earnings beat expectations in Q4 2025 and Q1 2026, while the company is actively expanding AI collaborations in healthcare and financial services, as reported by PRNewsWire on June 24, 2026.
The stock offers a moderate valuation with a P/E of 13.81 and consensus price target of $12.14, suggesting modest upside. Risks include competitive pressures from AI automation and volatile IT spending, but institutional sentiment is mixed with 37.5% buy ratings. The dividend yield adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
